SG11201503395TA - ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα - Google Patents
ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNαInfo
- Publication number
- SG11201503395TA SG11201503395TA SG11201503395TA SG11201503395TA SG11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA
- Authority
- SG
- Singapore
- Prior art keywords
- ifnα
- modulation
- compounds useful
- alkyl amide
- pyrimidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723827P | 2012-11-08 | 2012-11-08 | |
| PCT/US2013/068866 WO2014074670A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503395TA true SG11201503395TA (en) | 2015-05-28 |
Family
ID=49667570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503395TA SG11201503395TA (en) | 2012-11-08 | 2013-11-07 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9540333B2 (en) |
| EP (1) | EP2917186B1 (en) |
| JP (1) | JP6266639B2 (en) |
| KR (1) | KR102205914B1 (en) |
| CN (1) | CN104903301B (en) |
| AU (1) | AU2013341195B2 (en) |
| BR (1) | BR112015009798A2 (en) |
| CA (1) | CA2890935A1 (en) |
| EA (1) | EA028052B1 (en) |
| ES (1) | ES2648226T3 (en) |
| IL (1) | IL238605A (en) |
| MX (1) | MX2015005561A (en) |
| SG (1) | SG11201503395TA (en) |
| WO (1) | WO2014074670A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505748B2 (en) | 2012-11-08 | 2016-11-29 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
| ES2702126T3 (en) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha |
| KR102477063B1 (en) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES |
| CN107857754B (en) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | A kind of compound and its application in preparing preventing/treating medicine for treating rheumatoid arthritis |
| UY38144A (en) | 2018-03-12 | 2019-10-31 | Abbvie Inc | INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE |
| TWI842978B (en) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| SG11202112043PA (en) | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CA3207819A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| TW202246232A (en) | 2021-02-19 | 2022-12-01 | 英商蘇多生物科學有限公司 | Tyk2 inhibitors and uses thereof |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| CA2490888C (en) * | 2002-06-28 | 2011-05-24 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxamide derivative |
| KR20050019797A (en) * | 2002-06-28 | 2005-03-03 | 야마노우치세이야쿠 가부시키가이샤 | Diaminopyrimidinecarboxamide derivative |
| ATE542802T1 (en) * | 2004-09-30 | 2012-02-15 | Tibotec Pharm Ltd | HIV-INHIBITING 5-SUBSTITUTED PYRIMIDINES |
| WO2006068770A1 (en) * | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| DK2004632T3 (en) * | 2006-03-30 | 2014-06-16 | Janssen R & D Ireland | HIV INHIBITIVE 5-AMIDOSUBSTITUTED PYRIMIDINES |
| KR20090031787A (en) * | 2006-07-21 | 2009-03-27 | 노파르티스 아게 | 2,4-di(arylamino)-pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| EP2323993B1 (en) * | 2008-04-16 | 2015-06-03 | Portola Pharmaceuticals, Inc. | 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| WO2009145856A1 (en) * | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| EP2440204B1 (en) * | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| WO2011065800A2 (en) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same |
| CN111499580A (en) * | 2011-04-22 | 2020-08-07 | 西格诺药品有限公司 | Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| US9505748B2 (en) | 2012-11-08 | 2016-11-29 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| CA2890929A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses |
| AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
-
2013
- 2013-11-07 AU AU2013341195A patent/AU2013341195B2/en not_active Ceased
- 2013-11-07 EA EA201590911A patent/EA028052B1/en not_active IP Right Cessation
- 2013-11-07 EP EP13795913.6A patent/EP2917186B1/en active Active
- 2013-11-07 WO PCT/US2013/068866 patent/WO2014074670A1/en active Application Filing
- 2013-11-07 CA CA2890935A patent/CA2890935A1/en not_active Abandoned
- 2013-11-07 MX MX2015005561A patent/MX2015005561A/en unknown
- 2013-11-07 BR BR112015009798A patent/BR112015009798A2/en not_active Application Discontinuation
- 2013-11-07 US US14/441,213 patent/US9540333B2/en active Active
- 2013-11-07 SG SG11201503395TA patent/SG11201503395TA/en unknown
- 2013-11-07 JP JP2015541885A patent/JP6266639B2/en active Active
- 2013-11-07 ES ES13795913.6T patent/ES2648226T3/en active Active
- 2013-11-07 CN CN201380069688.2A patent/CN104903301B/en active Active
- 2013-11-07 KR KR1020157011660A patent/KR102205914B1/en active IP Right Grant
-
2015
- 2015-05-04 IL IL238605A patent/IL238605A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6266639B2 (en) | 2018-01-24 |
| EA028052B1 (en) | 2017-10-31 |
| EP2917186B1 (en) | 2017-10-18 |
| JP2016501185A (en) | 2016-01-18 |
| CN104903301B (en) | 2017-08-29 |
| WO2014074670A1 (en) | 2014-05-15 |
| EP2917186A1 (en) | 2015-09-16 |
| ES2648226T3 (en) | 2017-12-29 |
| US9540333B2 (en) | 2017-01-10 |
| MX2015005561A (en) | 2015-07-23 |
| AU2013341195B2 (en) | 2017-09-21 |
| KR102205914B1 (en) | 2021-01-20 |
| US20150299139A1 (en) | 2015-10-22 |
| KR20150079678A (en) | 2015-07-08 |
| CA2890935A1 (en) | 2014-05-15 |
| IL238605A (en) | 2017-05-29 |
| IL238605A0 (en) | 2015-06-30 |
| AU2013341195A1 (en) | 2015-07-02 |
| CN104903301A (en) | 2015-09-09 |
| EA201590911A1 (en) | 2015-10-30 |
| BR112015009798A2 (en) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300025I1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha | |
| IL238605A0 (en) | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifnα | |
| IL238554A0 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses | |
| IL253950A0 (en) | Bicyclically substituted uracils and the use thereof | |
| IL235216A0 (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| EP3083606A4 (en) | Pyrimidines and use thereof | |
| IL241823B (en) | C. novyi containing compositions and uses thereof in treating solid tumors | |
| EP3046417A4 (en) | Methods of using adipose tissue-derived cells in the modulation of pain and/or fibrosis | |
| HK1175159A1 (en) | Graphite block and the preparation method thereof | |
| EP3036849A4 (en) | Bs and ue, and methods used in the same | |
| GB201322892D0 (en) | Surface and composition | |
| EP2747777A4 (en) | Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures | |
| AU2013902966A0 (en) | Improvements in shoes and the like |